Access to routinely collected health data for clinical trials - review of successful data requests to UK registries. by Lensen, Sarah et al.
RESEARCH Open Access
Access to routinely collected health data
for clinical trials – review of successful data
requests to UK registries
Sarah Lensen1 , Archie Macnair1 , Sharon B. Love1* , Victoria Yorke-Edwards1 , Nurulamin M. Noor1 ,
Meredith Martyn1 , Alexandra Blenkinsop1 , Carlos Diaz-Montana1 , Graham Powell2 , Elizabeth Williamson3 ,
James Carpenter1,4† and Matthew R. Sydes1†
Abstract
Background: Clinical trials generally each collect their own data despite routinely collected health data (RCHD)
increasing in quality and breadth. Our aim is to quantify UK-based randomised controlled trials (RCTs) accessing
RCHD for participant data, characterise how these data are used and thereby recommend how more trials could
use RCHD.
Methods: We conducted a systematic review of RCTs accessing RCHD from at least one registry in the UK between
2013 and 2018 for the purposes of informing or supplementing participant data. A list of all registries holding RCHD
in the UK was compiled. In cases where registries published release registers, these were searched for RCTs
accessing RCHD. Where no release register was available, registries were contacted to request a list of RCTs. For
each identified RCT, information was collected from all publicly available sources (release registers, websites,
protocol etc.). The search and data extraction were undertaken between January and May 2019.
Results: We identified 160 RCTs accessing RCHD between 2013 and 2018 from a total of 22 registries; this
corresponds to only a very small proportion of all UK RCTs (about 3%). RCTs accessing RCHD were generally large
(median sample size 1590), commonly evaluating treatments for cancer or cardiovascular disease. Most of the
included RCTs accessed RCHD from NHS Digital (68%), and the most frequently accessed datasets were mortality
(76%) and hospital visits (55%). RCHD was used to inform the primary trial (82%) and long-term follow-up (57%).
There was substantial variation in how RCTs used RCHD to inform participant outcome measures. A limitation was
the lack of information and transparency from registries and RCTs with respect to which datasets have been
accessed and for what purposes.
Conclusions: In the last five years, only a small minority of UK-based RCTs have accessed RCHD to inform
participant data. We ask for improved accessibility, confirmed data quality and joined-up thinking between the
registries and the regulatory authorities.
Trial registration: PROSPERO CRD42019123088.
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Background
Randomised controlled trials (RCTs) are the gold-
standard method for evaluating health-care interventions
and their results impact on policy, practice, and patient
care. Substantial resources are dedicated to the collec-
tion of trial data and participant follow-up. Conse-
quently, the costs of conducting large trials are
substantial, maybe in the order of millions of pounds [1].
However, many national databases and registries collect
data that map to common important health-care events
such as hospital admission, cancer registration and
death. Use of this routinely collected health data
(RCHD) to replace or supplement traditional data cap-
ture should reduce trial costs, enabling a greater number
of large, definitive trials and efficient long-term assess-
ment of health-care interventions.
This explains why the use of RCHD in RCTs has been
labelled a disruptive technology (i.e. a technology that
transforms current practice) [2]. A model exemplar is
the TASTE (Thrombus Aspiration in ST-Elevation Myo-
cardial Infarction in Scandinavia) trial, which randomly
assigned 7244 participants in two years within national
Swedish registries, collected participant data from regis-
tries and yielded high-impact results at a small fraction
of the cost of traditional RCTs (USD $300,000 or $50
per patient) [3, 4]. The UK holds a large number of
rich health datasets, linkable through a unique Na-
tional Health Service (NHS) number. The availability
of these datasets is growing, as are the technological
capabilities of processing and storing these data. In
response to this, Health Data Research (HDR) UK
was established with the ambition of unleashing the
potential of RCHD to deliver “Better, Faster and More
Efficient Trials” [5].
However, while RCHD is already being harnessed to
enhance UK RCTs, anecdotal evidence suggests that
substantial barriers remain. Therefore, this systematic
review set out to identify and characterise RCTs acces-
sing RCHD in the UK to inform participant data, to de-
scribe how RCTs use these data, and to prioritise issues
that need to be addressed.
Methods
We conducted a systematic review of RCTs that have
accessed RCHD to inform or supplement trial data.
Eligibility
RCHD was defined as data that are collected for “admin-
istrative and clinical purposes without specific a priori
research goals” [6]. This included large, national, admin-
istrative resources (e.g. NHS Digital) and national dis-
ease and health-care audits and registries in each UK
devolved nation (e.g. the National Emergency Laparot-
omy Audit). Hereafter, we refer to these collectively as
registries. Cohort studies, biobanks, NHS Safe Havens
and electronic health records held only at the point of
care, such as primary care records held within general
practitioner (GP) practices, were excluded.
Eligible RCTs received RCHD from a registry between
2013 and 2018. This time frame was selected to broadly
align with the initiation of release registers in large na-
tional databases following the 2014 Partridge Review [7].
For each included RCT, any additional access to RCHD
from another registry and any previous access of RCHD
prior to 2013 were also captured.
Eligible RCTs were those that accessed RCHD to in-
form either baseline or outcome measure data of trial
participants. For at least one outcome measure, RCHD
must have been used for any combination of the follow-
ing: (i) replacing conventionally collected trial data, (ii)
cross-checking against existing trial data (including
participant-reported data), (iii) cross-checking RCHD
from different sources, (iv) triggering the trial team to
further investigate a possible outcome measure or event,
(v) cost-effectiveness analysis and (vi) solely methodo-
logical purposes. This was captured separately for (a) the
primary reporting period of the trial (i.e. baseline data or
an outcome measure within the follow-up for capturing
the primary trial outcome measure) and (b) long-term
follow-up.
We excluded RCTs if the RCHD was accessed only to
plan or facilitate recruitment (e.g. to contact patients
with an invitation of RCT enrolment) or to extrapolate
results of RCTs to broader populations. The protocol for
this review was registered with PROSPERO at the stage
of screening and data collection (CRD42019123088, reg-
istered 20 February 2019).
RCT identification
First, we compiled a list of registries (health-care data-
bases, registries and audits) in the UK through internet
searching, the Health Quality Improvement Program
(HQIP) directory [8], contact with government and
contracted organisations, and existing knowledge of UK
registries (more information on registries approached in
Additional file 1). Release registers were identified where
possible; these are lists of all data released from a given
registry, often including the purpose for which the data
will be used and the specific datasets accessed. Where
these were not available, registries were contacted to re-
quest a list of RCTs to which they had released RCHD.
Release registers from each source were de-duplicated
prior to screening (to remove multiple instances of data
releases for the same RCT from an individual registry).
The resultant list was searched for eligible RCTs by fil-
tering for entries containing one or more of the follow-
ing terms: rand*, trial, RCT, study, placebo and phase.
The search results were screened independently for
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potentially eligible RCTs by two authors. Disagreements
were resolved by discussion and re-checking.
Data collection and analysis
For each RCT identified, we sought information from
within the release registers (e.g. ‘statements of purpose’),
RCT websites (including privacy statements, publica-
tions, protocols, statistical analysis plans, patient infor-
mation sheets and consent forms) and other available
sources, including trial registration information. Publica-
tions for each RCT were searched for in major dissemin-
ation databases (e.g. MEDLINE and Google Scholar).
More information about data collection is given in an
Additional file 4.
Data collection included information about the RCT
(e.g. disease category, recruitment and publication status,
and primary outcome measure), the registry (e.g. NHS
Digital), the RCHD accessed (e.g. Hospital Episode Sta-
tistics) and the way in which the data were used (e.g.
linkage identifiers used and category of data use). Owing
to the large number of RCTs identified, we focussed
more detailed data collection of information on the data-
sets accessed and the way in which the data were used
to RCTs accessing RCHD between 2017 and 2018. Two
authors independently extracted data onto a piloted data
extraction form, and any disagreements were resolved by
discussion and re-checking. Data were subsequently en-
tered into a clinical data management system (Elsevier’s
MACRO [9]), and descriptive analyses were undertaken
in Stata (version 15.1, [10]). Trial teams were not con-
tacted for information or clarification. To enable a broad
comparison of this cohort of RCTs with those conducted
in the UK, we compared the descriptive characteristics
of these RCTs with those reported in a recent cross-
sectional analysis of UK Health Research Authority
(HRA) approved RCTs [11].
Patient and public involvement
No patients were involved in any component of the de-
sign, production, analysis, interpretation or writing up of
the results of this review. We plan to disseminate the
final results to the HDR UK Public Advisory Board and
request that they disseminate the manuscript within
their network as appropriate.
Results
Results of the search
The search and extraction of data were undertaken be-
tween January and May 2019; 74 UK registries holding
RCHD were identified and 13 of these maintained ac-
cessible release registers (Fig. 1).
Fig. 1 Identification of trials from registries. Each trial is counted only once. For instance, trials identified through both release register searches
and notification by registries are captured only once. Of 13 registries with release registers available, 10 published comprehensive release registers
and three provided a brief lists of projects receiving routinely collected health data (RCHD) on the website
Lensen et al. Trials          (2020) 21:398 Page 3 of 11
These release registers listed more than 6000 unique
data releases; 2918 releases were identified in the search.
These were manually screened and 141 RCTs were iden-
tified, corresponding to 2% (141/6251) of the total re-
leases. The remaining 61 registries were contacted to
request information about RCTs having accessed RCHD,
resulting in a further 19 RCTs identified from eight
registries. During the data extraction, we discovered one
trial that had received data from one of the registries
which had not otherwise provided a list of trials. This
gave a total of 160 RCTs accessing RCHD from 22 regis-
tries between 2013 and 2018 (Fig. 1). Although all RCTs
had accessed RCHD between 2013 and 2018, they were
conducted in varying time periods; recruitment start
dates ranged from 1979 to 2018. Detailed data collec-
tion, for trials accessing data in 2017–18, involved 91
out of 160 trials.
RCT characteristics
The 160 included RCTs were generally large (median
sample size 1590, range 41–6,000,000), although 11%
(17/160) described themselves as pilot or feasibility trials
(Table 1). The majority (85%, 136/160) were individually
randomised trials, and 15% (24/160) were cluster-
randomised. The most common disease categories were
cancer (29%, 47/160) and cardiovascular disease (29%,
46/160), and the most common primary outcome meas-
ure was survival/death (45%, 72/160). Only 20% (32/160)
of the RCTs were international, recruiting at additional
sites outside of the UK. A small number of RCTs had
publications available which included outcome measures
informed by access to RCHD. Of these, 83% (29/35) had
one or more results published in a high-profile medical
journal.
The majority of RCTs were clearly coordinated through
a UK Clinical Research Collaboration (UKCRC)-registered
clinical trials unit (CTU): 64% (103/160) were coordinated
by a registered CTU, 14% (22/160) were not and 22% (35/
160) were unclear) (Table 1). Of all 51 currently registered
CTUs, 63% (32/51) had accessed RCHD for at least one
RCT in this cohort. Of these CTUs, the median number
of RCTs from this cohort was 2 (range 1–11).
RCTs accessing RCHD were more often conducted in
cancer and cardiovascular populations compared with
RCTs submitted for an ethical opinion via the HRA in
2015 (29% vs. 10% and 29% vs. 17%, respectively) and
were more likely to recruit from primary care settings
(26% vs. 5%), to be based only in the UK (78% vs. 50%)
and to be cluster-randomised (15% vs. 3%). RCHD RCTs
had larger sample sizes on average (median 1590 vs.
275) than those submitted to the HRA (Table 2). RCTs
accessing RCHD were less likely to be feasibility/pilot
studies (11% vs. 18%). We identified 160 trials accessing
RCHD over a five-year period (32 trials per year), which
is equivalent to about 3% (32/963) of all RCTs approved
by the HRA in 2015.
RCHD access and use
NHS Digital was by far the most commonly accessed
registry: 68% (108/160) trials accessed RCHD from NHS
Digital (Table 3). The second most common was the In-
formation Services Division in Scotland 22% (35/160).
Most of the RCTs accessed RCHD from one registry
(79%, 126/160); 14% (22/160) accessed data from two
registries, 5% (8/160) from three registries, and 3% (4/
160) from four or more. A small number of RCTs were
completely embedded (i.e. participants were recruited
from and followed up) in the registry (12%, 11/91).
Of the 160 RCTs, 91 had received a total of 134 data
releases in the years 2017–2018 and were selected for
detailed data extraction. Identifiers used for linkage were
often unclear (46%, 62/134); however, when assessable,
the most common fields were NHS Number (94%, 68/
72), date of birth (85%, 61/72) and participant name
(56%, 40/72) (an additional file shows Additional file 2:
Table S2). The most common datasets accessed were
mortality (76%, 69/91), hospital visits (55%, 50/91) and
cancer registration (32%, 29/91) (Table 3). Almost half
of the included RCTs (47%, 43/91) accessed RCHD to
inform the primary trial outcome measure. Of RCTs
using RCHD only for at least one outcome measure,
38% (20/52) were drug trials; 40% of RCTs (36/91)
accessed RCHD for both the primary and long-term
follow-up (Table 4); 21% of RCTs (19/91) accessed one
or more RCHD only for long-term follow-up and 45%
(41/91) accessed one or more RCHD exclusively for the
primary with no obvious planned long-term follow-up.
Most commonly, RCHD alone was used for at least
one trial outcome measure (57%, 52/91) (Table 4). One
third of RCTs used RCHD for cross-checking, either of
trial data (30%, 27/91) or participant-reported data (31%,
28/91). Use of RCHD to trigger case review was also
common (24%, 22/91), as was use of the data to conduct
cost-effectiveness analysis (27%, 25/91). Use of RCHD
for methodological reasons was uncommon (12%, 11/
91), as was release for comparison of two or more
RCHD sources (10%, 9/91). RCTs using RCHD for long-
term follow-up were more likely to use RCHD alone to
inform outcome measures and less likely to conduct
cross-checking against trial or participant-reported data
or to use the data for methodological purposes. Overall,
there was substantial variation in how trials used RCHD
to inform participant outcome measures. For example,
among the 74 trials using RCHD within the primary
reporting period, 37 different combinations of data use
were captured (an additional file shows Additional file 3:
Table S3). Among the 36 RCTs using RCHD for the pri-
mary report and long-term follow-up, 56% (20/36) used
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Table 1 Trial characteristics
Trial characteristic Summary extraction: 2013–16,
n (%)
n = 69
Detailed extraction: 2017–18,
n (%)
n = 91
Total,
n (%)
n = 160
Purpose
Screening 6 (9%) 10 (11%) 16 (10%)
Treatment 51 (74%) 65 (71%) 116 (73%)
Primary prevention 12 (17%) 16 (18%) 28 (18%)
Feasibility/Pilot trial
Yes 6 (9%) 11 (12%) 17 (11%)
No 63 (91%) 80 (88%) 143 (89%)
Recruitment setting
Primary care 23 (33%) 18 (20%) 41 (26%)
Secondary care 46 (67%) 73 (80%) 119 (74%)
Disease category
Cancer 17 (25%) 30 (33%) 47 (29%)
Cardiovascular and stroke 21 (30%) 25 (27%) 46 (29%)
Pregnancy and childbirth 4 (6%) 5 (5%) 9 (6%)
Mental/neurological health 6 (9%) 6 (7%) 12 (8%)
Infection 5 (7%) 3 (3%) 8 (5%)
Endocrine and diabetes 1 (1%) 3 (3%) 4 (3%)
Inflammatory disorder 2 (3%) 3 (3%) 5 (3%)
Other 13 (19%) 16 (18%) 29 (18%)
Intervention
Drug 38 (55%) 38 (42%) 76 (48%)
Surgical 5 (7%) 8 (9%) 13 (8%)
Other 26 (38%) 45 (49%) 71 (44%)
Primary outcome
Survival related 33 (48%) 39 (43%) 72 (45%)
Other 36 (52%) 52 (57%) 88 (55%)
Randomisation
Individual 61 (88%) 75 (82%) 136 (85%)
Cluster 8 (12%) 16 (18%) 24 (15%)
Trial size
Median 1103 2611 1590
Range 41–170,432 53–6,000,000 41–6,000,000
1–500 21 (30%) 20 (22%) 41 (26%)
500–5000 31 (45%) 43 (47%) 74 (46%)
>5000 17 (25%) 25 (27%) 42 (26%)
Unclear 0 (0%) 3 (3%) 3 (2%)
International accrual
Yes 13 (19%) 19 (21%) 32 (20%)
No (UK only) 56 (81%) 69 (76%) 125 (78%)
Unclear 0 (0%) 3 (3%) 3 (2%)
Coordinated by registered clinical trials unit
Yes 40 (58%) 63 (69%) 103 (64%)
No 10 (14%) 12 (13%) 22 (14%)
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the data differently for these two stages of the study for
at least one outcome measure (e.g. shifting from cross-
checking of trial data for the primary reporting to RCHD
only during the long-term follow-up).
Discussion
The increase in the scope, accessibility and richness of
RCHD presents an unprecedented opportunity for better
health research [12]. Use of RCHD for trial outcome
measures may be a cost-effective means of obtaining
data, limiting the burden on trial staff and participants
in attending for trial visits or replying to questionnaires,
especially for longer-term data collection. Use of RCHD
may also minimise attrition in RCTs where datasets have
national coverage, reduce issues of self-reported out-
come measures which are prone to recall bias (e.g. recal-
ling diagnoses or operations from hospital visits) and
could limit ascertainment bias where the clinicians and
coders are not aware of trial participation. However, are
RCHD replacing case report forms in clinical trials and,
if not, why not?
To the best of our knowledge, this is the first review
to summarise the accessing of RCHD by randomised tri-
als in the UK by reviewing the sources of data and the
first to assess the use of these data specifically for trial
outcome measure assessment. We identified 160 trials
accessing RCHD to inform participant data from 22
registries in the UK between 2013 and 2018, and many
(47%, 43/91) used it for the primary outcome measure.
This corresponds to about 32 trials a year, which is
about 3% of the trials seeking HRA approval annually
[11]. Alongside this, RCTs accessing RCHD accounted
for only 2% of the data releases from included registries.
Since most trial patient data are captured in the hospital
records, this suggests that the potential of RCHD in tri-
als is largely untapped.
Table 1 Trial characteristics (Continued)
Trial characteristic Summary extraction: 2013–16,
n (%)
n = 69
Detailed extraction: 2017–18,
n (%)
n = 91
Total,
n (%)
n = 160
Unclear 19 (28%) 16 (18%) 35 (22%)
Highest profile journal (if primary report published)
BMJ NA 2 (2%) 2 (1%)
JAMA NA 6 (7%) 6 (4%)
Lancet NA 16 (18%) 16 (10%)
Lancet-specialty NA 2 (2%) 2 (1%)
NEJM NA 3 (3%) 3 (2%)
Other NA 6 (7%) 6 (4%)
Not yet published NA 56 (62%) 56 (35%)
Not captured 69 (100%) NA 69 (43%)
Table 2 Comparison of RCTs accessing RCHD with trials
evaluated by the HRA in 2015
RCTs accessing RCHD
(n = 160)
HRA in 2015a
(n = 963b)
Recruitment setting
Primary care 41 (26%) 48 (5%)
Secondary care 119 (74%) 846 (95%)
Unclear/missing 0 69
Therapeutic area
Cancer 47 (29%) 168 (17%)
Cardiovascular and stroke 46 (29%) 121 (13%)
Pregnancy and childbirth 9 (6%) 30 (3%)
Infection 8 (5%) 55 (6%)
Inflammatory disorder 5 (3%) 72 (7%)
Drug trial 76 (48%) 515 (53%)
Randomisation
Individual 136 (85%) 934 (97%)
Cluster trial 24 (15%) 29 (3%)
Feasibility/pilot 17 (11%) 177 (18%)
Sample size (median, range) 1590 (41–6,000,000) 275 (6–30,000)
Unclear/missing 0 440
Recruitment location
UK only 125 (78%) 450 (50%)
International trials 32 (20%) 443 (50%)
Unclear/missing 0 70
This table only includes data fields that were comparable between the two
sources. Sample size targets in the UK Health Research Authority (HRA) cohort
are limited to those not described as phase I/II trials. Data obtained from Clark
et al. [11] (2018), including unpublished supplementary appendices [1].
Abbreviations: RCHD routinely collected health data, RCT randomised
controlled trial
aClark et al. [11].
bFor recruitment setting and location, the unclear/missing values were omitted
from the percentage calculation.
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We observed considerable variation in the use of
RCHD, most commonly to inform or supplement out-
come measures in primary trial report and long-term
follow-up. Only 52 (57%) out of 91 used RCHD alone
for the collection of at least one trial outcome measure;
that is, even when used, the data are duplicated from
trial-specific sources – further evidence that the poten-
tial of RCHD is largely unrealised.
Only a very small proportion of UK trials appear to be
successfully accessing RCHD. Our findings are consist-
ent with anecdotal evidence that one barrier to greater
access and use may be lack of awareness among trialists
regarding the availability and potential utility of this in-
formation for trial follow-up. There is no national direc-
tory of registries which lists sources of RCHD available
to researchers. The National Institute for Health Re-
search (NIHR) Health Data Finder for Research contains
only 18 datasets [13]. Half of the registries identified for
this review confirmed that they had not provided data to
RCTs and may represent an underutilised resource.
Both for us (as reviewers) and for trialists, the lack of a
comprehensive list of RCHD registries and the data they
hold is a challenge. Furthermore, the majority of regis-
tries we identified did not maintain a register of ap-
proved data releases. A number of release registers had
brief information (e.g. only application titles), and some
registries were unable to advise whether their RCHD
had been released for this purpose. Therefore, our search
may have missed eligible trials. For trialists, this makes it
more difficult to keep abreast of how these data may be
Table 3 Registries and datasets accessed
Registry Total trials
n = 160
Total trials
(2017–2018)
n = 91
Datasets accessed
Total trials (2017–2018) n = 91
Death
n = 69
Hospital visits n = 50 Cancer registration n = 29 Other n = 26
NHS Digital 108 (68%) 59 (65%) 58 (84%) 34 (68%) 22 (76%) 4 (15%)
ISD-Scotland 35 (22%) 25 (27%) 16 (23%) 13 (26%) 7 (24%) 2 (8%)
PHE 15 (9%) 11 (12%) 3 (4%) 6 (12%) 10 (34%) 1 (4%)
SAIL 9 (6%) 6 (7%) 2 (3%) 5 (10%) 2 (7%) 1 (4%)
ICNARC 7 (4%) 4 (4%) 1 (1%) 0 (0%) 0 (0%) 4 (15%)
NWIS 7 (4%) 6 (7%) 1 (1%) 6 (12%) 1 (3%) 0 (0%)
PICANet 6 (4%) 2 (2%) 0 (0%) 0 (0%) 0 (0%) 2 (8%)
CPRD 4 (3%) 1 (1%) 0 (0%) 1 (2%) 0 (0%) 1 (4%)
NHSBT 3 (2%) 3 (3%) 0 (0%) 0 (0%) 0 (0%) 2 (8%)
TARN 3 (2%) 2 (2%) 1 (1%) 1 (2%) 0 (0%) 2 (8%)
NELA 2 (1%) 2 (2%) 0 (0%) 0 (0%) 0 (0%) 2 (8%)
NNRD 2 (1%) 2 (2%) 1 (1%) 1 (2%) 0 (0%) 2 (8%)
PHW 2 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 1 (4%)
UKRR 2 (1%) 2 (2%) 0 (0%) 1 (2%) 1 (3%) 0 (0%)
ResearchOne 2 (1%) 2 (2%) 0 (0%) 0 (0%) 0 (0%) 2 (8%)
DOH 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
FFFAP 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 1 (4%)
HBS 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 1 (4%)
NICOR 1 (1%) 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%)
NICR 1 (1%) 1 (1%) 0 (0%) 0 (0%) 1 (3%) 0 (0%)
OHCAO 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 1 (4%)
UKCFR 1 (1%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 1 (4%)
Registries accessed was captured for all 160 trials. Information about datasets accessed from these registries was captured only for those 91 accessing routinely
collected health data (RCHD) between 2017 and 2018. The fields are not mutually exclusive as one trial may have accessed data from multiple registries, and
multiple datasets can be accessed via a single registry. Percentages are calculated by using the column header denominators. Hospital visits includes all Hospital
Episode Statistics (Outpatient, Inpatient, Accident and Emergency, and Critical Care), Patient Episode Database for Wales (PEDW), and Scottish Morbidity Records
(SMR). Acronyms: Information Services Division (ISD), Public Health England (PHE), Secure Anonymised Information Linkage (SAIL), Intensive Care National Audit &
Research Centre (ICNARC), NHS Wales Informatics Service (NWIS), Paediatric Intensive Care Audit Network (PICANet), Clinical Practice Research Datalink (CPRD),
NHS Blood and Transplant (NHSBT), Trauma Audit and Research Network - Major Trauma Audit (TARN), National Emergency Laparotomy Audit (NELA), Neonatal
Research Database (NNRD), Public Health Wales (PHW), UK Renal Registry (UKRR), Department of Health (DOH), Falls and Fragility Fractures Audit programme
(FFFAP), Honest Broker Service, Northern Ireland Statistics and Research Agency (HBS), National Institute for Cardiovascular Outcomes Research (NICOR), Northern
Ireland Cancer Registry (NICR), Out-of-Hospital Cardiac Arrest Outcomes (OHCAO) Registry, UK Cystic Fibrosis Registry (UKCFR)
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used, hindering the uptake of RCHD by the commu-
nity. A further barrier is that many publications about
the included trials which were expected to include
RCHD made no mention of it. So it was often not
clear from publically available sources exactly how
RCHD would be used with a trial. (Note that we de-
liberately did not contact trial teams for information
or clarification, as our aim was to assess information
that was publically available.) The forthcoming CON-
SORT extension for RCTs using cohorts and routinely
collected health data will cover trials accessing elec-
tronic health records and should help to improve
transparency in reporting [14] and enable the com-
munity to keep abreast of developments.
Other recent reviews in this area have summarised
characteristics of trials in other settings, including those
using these data for at least one trial outcome measure
[15, 16] and for the long-term extension of completed
trials [17, 18]. These reviews identified similar types of
trials accessing RCHD in terms of trial characteristics.
However, owing to the traditional literature searches
employed by these reviews, they identified only a handful
of the UK trials identified here; by reviewing release reg-
isters rather than publications, we found that more trials
are receiving data than are mentioning it in their
publications.
Reliance on data provision from registries raises un-
predictable, and potentially extremely time-consuming,
challenges relating to data access and retention. For ex-
ample, changes to registry names can render participant
consent invalid if it no longer references the correct pro-
vider name. Individuals at registry organisations are also
known to have provided contrary information on specific
consent form wording [19]. Many researchers report
long delays in the application process, impacting on
timely data collection and trial completion, and there
were reports that RCTs were unable to publish trial re-
sults because of issues with data access [20]; in one
RCT, failure to gain access to mortality data necessitated
a change to the primary trial outcome measure [21].
Cancer registration data, collected by Public Health Eng-
land, have previously been available through NHS
Digital; however, provision of these data stopped for a
period of more than two years. Such unscheduled lapses
in data availability introduce substantial risk for RCTs
relying on these cancer registration notifications through
this route. One RCT reported failure by the registry to
update flagging of new patients as recruitment contin-
ued: the trial team received death information only for
the initial half of their cohort [22]. Additionally, many
registries do not permit ongoing retention or onward
sharing of the datasets, creating conflict with key trial
Table 5 Barriers to use of routinely collected health data and potential solutions
Barrier Example/explanation Potential solution
Lack of comprehensive list of RCHD
sources and the data they hold
There is no one point where you can find out about
all sources of RCHD.
A searchable database – HDR UK or NHS Digital is
responsible for update.
Clear terminology to describe data
from registries
The source of the trial data is not always mentioned
in trial publications.
Publication of consensus terminology and a
description of the way in which RCHD can
be used.
Publications of trials using RCHD did
not make mention of it.
In methods section, details of the sources of RCHD
should be stated.
Soon-to-be-released EHR CONSORT extension
for routinely collected health data should
improve this.
Lack of awareness by trialists of the
availability and utility of RCHD
Shown by a small percentage of trials using RCHD More publicity on available RCHD and the use
of RCHD
Poor accessibility of data Registry name change invalidating consent
Long delays of several years in application process
RCHD not provided despite agreement
Streamline the RCHD application process and
render it efficient.
Poor data retention and no possibility
of onward sharing
Time limit to keeping the data is shorter than the
data storage time limit for the trial.
Data sharing is often necessary to achieve funding
for a trial.
RCHD needs to align with trial data retention
rules and data-sharing requirements.
Data quality and timeliness Trial data are monitored and checked and a lot of
registry data are not.
Registry data need a validation process to ensure
that their RCHD can be used as a verifiable
GCP-compliant data source.
A comparison of trial and registry data in several trials,
facilitated by a SWAT, is required to educate all about
the accuracy and completeness of registry data.
Regulator ready RCHD Trial data require underlying source data whilst
registry data are not source data and do not often
have checked underlying source data.
Regulators and registries need to agree a solution
to underlying source data.
Abbreviations: EHR CONSORT electronic health record Consolidated Standards of Reporting Trials, GCP Good Clinical Practice, HDR UK Health Data Research UK,
NHS National Health Service, RCHD routinely collected health data, RCT randomised controlled trial, SWAT study-within-a-trial
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processes such as data archiving, data sharing and indi-
vidual participant data meta-analysis [19, 23].
The administrative nature of some RCHD sources, the
external coding and validation processes employed, and
lack of oversight and visibility of data collection, pro-
cessing, and audit trails raise concerning implications for
Good Clinical Practice (GCP) adherence [24]. The data
used in clinical trials have to be the same as the source
data to be GCP-compliant. There are accounts of data
quality issues from RCHD, even for clearly objective out-
come measures such as death [25–27], although cardio-
vascular outcomes seem more promising [28]. A
standardised, systematic approach to data quality assess-
ment, ideally as a coordinated series of multi-RCT
studies-within-a-trial (SWATs), would provide empirical
evidence of the quality of RCHD and traditional trial
data. Registry processes for data collection and editing
would also need to be assessed.
The timeliness of RCHD is key. While primary care
data (e.g. held by Clinical Practice Research Datalink)
can be extracted easily from multiple GP practices
across software systems (Vision or EMIS), provision of
secondary care data such as Hospital Episode Statistics
generally has delayed capture and is received in batch
files every month or quarter. Certainly, these data cannot
be relied upon for the timely reporting of serious adverse
events (e.g. requiring hospital admission).
Conclusion
Only a tiny percentage of UK-based RCTs have accessed
RCHD in the last five years to inform participant data,
and few of these are exclusively relying on RCHD, al-
though most patient data are captured by hospital sys-
tems. Furthermore, while most RCTs appear to be using
similar datasets from a small number of registries, the
way in which the RCHD is used to inform or supple-
ment trial data appeared to vary substantially. Barriers to
lack of utilisation include access to data and fitness of
RCHD for research purposes.
Our review supports concerns that exploiting the po-
tential of RCHD in trials is hindered (Table 5). Targeting
resources to develop robust solutions to overcome these
hurdles and enable a step change for clinical trials is ur-
gently needed so that UK trials can fully harness the
power of RCHD to conduct more efficient RCTs.
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